{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022627","form_type":"8-K","ticker":"GNLX","cik":"0001231457","company_name":"GENELUX Corp","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.198451+00:00","generated_at":"2026-06-13T16:02:56.286409+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genelux provides Phase 3 enrollment timeline for Olvi-Vec and cash runway into Q1 2026","bullets":["Enrollment for Phase 3 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer expected to complete mid-2024 with 11-month follow-up.","Initial interim data for Phase 2 trial of Olvi-Vec in recurrent non-small-cell lung cancer expected as early as mid-2024.","Cash operating runway expected to extend into first quarter of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022627","json":"https://secwatch.observer/filing/0001493152-23-022627.json","markdown":"https://secwatch.observer/filing/0001493152-23-022627.md","text":"https://secwatch.observer/filing/0001493152-23-022627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1231457/000149315223022627/0001493152-23-022627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1231457/000149315223022627/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:02:56.286409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}